Florida Rep. Michael Grieco’s decision not to seek a new legislative term could negatively impact efforts to advance the legal use of psychedelics in the Sunshine State. The representative has been the most vocal advocate for psychedelics reform in the Florida Legislature. In 2021, Grieco filed a bill (HB 549) that would have legalized the
I recently published a nationwide psychedelics law roundup post. But in doing so, I realized that it’s been a while since we did a comprehensive California psychedelics update. Today, I’ll walk through the two key proposed California psychedelics laws and where they stand. California’s push to decriminalize (almost) all psychedelics In 2021, California Senator Scott
The gap in the treatment of controlled substances between the state and federal levels continues to widen. That has long been true with cannabis, but the trend has accelerated with psilocybin and other psychedelics recently. This growing disparity has implications under U.S. immigration law for employers and non-residents who wish to become involved in the
Psychedelics developments in 2021 covered everything from legalization and decriminalization to pharmaceutical advances and public company milestones.
DMT, or N, N-dimethyltryptamine is a powerful psychedelic. DMT, like its sister psychedelics (LSD, MDMA, psilocybin … and even marijuana), is a Schedule I controlled substance. So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back
In April of this year, Florida’s first attempt at psychedelics reform failed, as a House subcommittee rejected HB 549. This bill, introduced by Rep. Michael Grieco (D-Miami Beach), would have legalized the use of psilocybin for mental treatment in the nation’s third most populous state. Despite this setback, 2021 could yet be a pivotal year
Cannabis is legal and regulated in most U.S. states. Oregon legalized and will soon regulate psilocybin. Cities around the country decriminalized (and more are decriminalizing) a host of other psychedelics. Ketamine clinics are popping up around the county. Next up is MDMA (referred to in some forms as “ecstasy”). Today, we’re going to talk about
Microdose hosted its annual psychedelics conference in Miami last week (appropriately titled “Wonderland”). We were there, meeting industry insiders and clients, and keeping on the cutting edge of the psychedelics space. For our readers who weren’t able to make it, here are some of our key takeaways from two days of all things psychedelics: Everyone
Something strange happened yesterday. Psychedelics unicorn Compass Pathways released data for the largest clinical trial ever conducted of a psilocybin drug. Not only did the drug seem to work, but the heavily anticipated data were “breathtaking” in the words of Compass’ CEO. Immediately, the company’s publicly traded shares dropped 16%. Including the day prior, it
Public and scientific interest in psychedelics such as psilocybin and MDMA is expanding. Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Psilocybin, a
